Cyclooxygenases Inhibitors
1 drugsAbout Cyclooxygenases
Cyclooxygenases (COX enzymes) are crucial for producing prostaglandins, thromboxanes, and prostacyclins, signaling molecules involved in inflammation, pain, and fever.
Cyclooxygenases have long been therapeutic targets for pain management, but there is currently no genetic evidence data available linking cyclooxygenases to specific diseases.
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is the only FDA-approved drug targeting cyclooxygenases, formulated as a small molecule and approved in 1995.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Obesity with only 4 trials.
Top Drugs
STEVENS J is the only company with an approved drug targeting cyclooxygenases.
The lack of competition suggests high barriers to entry or limited market potential.
Clinical Trials 616 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 136 | 118 | 7 | 8 | 94% |
| Phase 2 | 116 | 74 | 19 | 22 | 80% |
| Phase 3 | 139 | 67 | 23 | 49 | 74% |
| Phase 4 | 225 | 135 | 28 | 59 | 83% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 6 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 391 clinical trials targeting Cyclooxygenases.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities